REG - Avacta Group PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AVTG.L</Origin>

AvactaAnnouncement

28/07/2017 13:20

RNS Number : 4617M
Avacta Group PLC
28 July 2017
28 July 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Director/PDMR Shareholding
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today transferred 87,850 ordinary shares of 10p each ("Ordinary Shares") from his personal holding to his self-invested personal pension (SIPP) at a price of 83.0p per Ordinary Share. Following this transaction, Dr Smith's total interest in Ordinary Shares has remained unchanged.
Enquiries:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel: +44 (0) 844 414 0452
www.avacta.com
finnCap Ltd
Geoff Nash / Giles Rolls - Nominated Adviser
Tim Redfern / Alice Lane - Corporate Broking
WG Partners
David Wilson
Nigel Barnes
Claes Spang
Tel: +44 (0) 207 220 0500
www.finncap.com
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
www.wgpartners.co.uk
Media Enquiries
FTI Consulting
Simon Conway / Natalie Garland-Collins
Tel: +44 (0) 203 727 1000
avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets. 
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. 
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Alastair Smith
2. 
Reason for the Notification
a)
Position/status
Chief Executive Officer
b)
Initial notification/Amendment
Initial notification 
3. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Avacta Group Plc 
b)
LEI
n/a
4. 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
Ordinary shares of 10p 
Identification code
GB00BYYW9G87
b)
Nature of the transaction
Transfer of ordinary shares to SIPP via a sale and purchase.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
83.0 pence
87,850
d)
Aggregated information:
 Aggregated volume
 Price
See above
e)
Date of the transaction
28 July 2017
f)
Place of the transaction
London Stock Exchange, AIM Market (XLON)

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHOKFDDBBKDQOB